Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma: Final appraisal document
In DRAFT guidance, NICE recommends use of this regimen in adults who have had lenalidomide and a proteasome inhibitor, whose disease progressed on their last treatment, only if they have had 3 previous treatment lines and conditions in the managed access agreement are followed.
Source:
National Institute for Health and Care Excellence